Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback